Full text is available at the source.
Weizmannia coagulans BC99 alleviates pediatric allergic rhinitis via the gut microbiota-SCFAs- immunomodulatory axis: A randomized, double-blind, placebo-controlled trial
Weizmannia coagulans BC99 may reduce children's allergic rhinitis by changing gut bacteria, short-chain fatty acids, and immune response
AI simplified
Abstract
Supplementation with Weizmannia coagulans BC99 significantly improved symptom control and quality of life in 52 children with allergic rhinitis.
- BC99 supplementation resulted in improved Rhinitis Control Assessment Test and Rhino-conjunctivitis Quality of Life Questionnaire scores compared to placebo.
- Significant reductions in serum levels of IgE, IL-4, IL-13, and TNF-α were observed, alongside increases in IFN-γ and the IFN-γ/IL-4 ratio.
- Gut microbiota analysis showed an increase in beneficial short-chain fatty acid-producing bacteria and a decrease in pro-inflammatory bacteria.
- Elevated fecal concentrations of acetic acid, butyric acid, and isovaleric acid were associated with BC99 supplementation.
- Correlation analysis indicated positive relationships between beneficial bacteria and short-chain fatty acids, as well as negative associations with inflammatory mediators.
- The intervention was well-tolerated, with no reported adverse events.
AI simplified